{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:34:59Z","timestamp":1779287699608,"version":"3.51.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With the increased use of cancer immunotherapy, a number of immune-related adverse events (irAEs) are being identified. These irAEs can be compared with known autoimmune disorders in similar tissues, with important similarities and differences. Understanding the etiology of irAEs may bring to light concepts applicable to immune responses in cancer, autoimmunity, and infectious disease. This immunobiology is especially relevant to cancer patients with preexisting allogeneic transplants or autoimmune disease who are undergoing cancer immunotherapy. To address these facets of cancer immunotherapy, academic leaders from these various disciplines discussed current irAE basic and clinical research, irAE diagnosis and management, and the need for biomarkers and algorithms to identify individuals at risk for irAEs at a conference jointly sponsored by the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, MD, on March 22\u201323, 2018. Mechanisms and models to characterize irAEs, standardize protocols, store biospecimens, and capture and analyze irAE data were also reviewed during the inaugural Cancer, Autoimmunity, and Immunology Conference. This summary highlights cancer immunotherapy\u2013induced irAEs, the challenges ahead, and the opportunities for greater understanding of autoimmune conditions.<\/jats:p>","DOI":"10.4049\/jimmunol.1900264","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T22:35:22Z","timestamp":1555367722000},"page":"2823-2828","source":"Crossref","is-referenced-by-count":4,"title":["Report on the 2018 Cancer, Autoimmunity, and Immunology Conference"],"prefix":"10.1093","volume":"202","author":[{"given":"Colleen S","family":"Curran","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Clinical Center, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie L","family":"Sommers","sequence":"additional","affiliation":[{"name":"ImmunoOncology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health , Rockville, MD 20850"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3118-5111","authenticated-orcid":false,"given":"Howard A","family":"Young","sequence":"additional","affiliation":[{"name":"Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Frederick, MD 21702"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Bourcier","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, MD 20852"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Mancini","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Disease Biology Program, Division of Extramural Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"2025030417562012100_r1","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"2025030417562012100_r2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.05.004","article-title":"The heart of the matter: protection of the myocardium from T cells","volume":"45","author":"Lichtman","year":"2013","journal-title":"J. Autoimmun."},{"key":"2025030417562012100_r3","doi-asserted-by":"crossref","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"2025030417562012100_r4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology"},{"key":"2025030417562012100_r5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? [Published erratum appears in 2017 Nat. Med. 23: 1004.]","volume":"23","author":"June","year":"2017","journal-title":"Nat. Med."},{"key":"2025030417562012100_r6","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"2025030417562012100_r7","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2025030417562012100_r8","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"2025030417562012100_r9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2025030417562012100_r10","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","article-title":"Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"key":"2025030417562012100_r11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"2025030417562012100_r12","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"2025030417562012100_r13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"2025030417562012100_r14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"2025030417562012100_r15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrd.2018.34","article-title":"INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology","volume":"17","author":"Khozin","year":"2018","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/10\/2823\/61871814\/ji1900264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/10\/2823\/61871814\/ji1900264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:55:52Z","timestamp":1741118152000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/202\/10\/2823\/7952136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1900264","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5]]}}}